James Gubbins is a UK-qualified partner in the London office of Morrison & Foerster. Mr. Gubbins has more than 17 years of experience in the provision of advice on IPOs and other securities issues, private equity transactions and mergers & acquisitions. His clients include corporates, private equity funds and investment banks.

Mr. Gubbins spent a number of years with Clifford Chance and joined Morrison & Foerster in 2005 from the London office of Weil, Gotshal & Manges.

• advising the shareholders of KuDOS, a privately-owned UK biotechnology company, in relation to the $210 million acquisition of KuDOS by Astrazeneca;
• advising Oxford Biomedica, a gene therapy company, on a proposed placing and open offer and related investment by Sigma-Aldrich to raise £30.1 million;
• advising ReNeuron, the UK-based adult stem cell research company, on its successful IPO on AIM;
• advising Silverjet plc on its IPO on AIM raising £24 million; and
• advising Microscience Holdings PLC and its institutional investors on the sale of Microscience Limited, a privately-held vaccine company to U.S.-based Emergent BioSolutions Inc.